Introduction
In a significant development for colorectal cancer (CRC) treatment, Bristol Myers Squibb (BMS) announced that its KRAS inhibitor Krazati (adagrasib) has received accelerated approval from the U.S. Food and Drug Administration (FDA). This approval is particularly for patients with the KRASG12C mutation, offering a new targeted therapy option in combination with cetuximab.
Background on Colorectal Cancer
Colorectal cancer is one of the most commonly diagnosed cancers worldwide. In the U.S. alone, over 106,000 new cases are expected to be diagnosed this year. Among these, approximately 4% of patients harbor the KRASG12C mutation, which has historically posed significant treatment challenges.
FDA Approval Details
The FDA’s accelerated approval of Krazati covers its use in combination with cetuximab for adults with locally advanced or metastatic CRC who have previously received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This approval is grounded in positive outcomes from the phase 1/2 KRYSTAL-1 study.
KRYSTAL-1 Study Insights
The KRYSTAL-1 study provided compelling evidence supporting Krazati’s efficacy. In this trial, the combination of Krazati and cetuximab achieved a confirmed objective response rate of 34% and a median duration of response of 5.8 months. These results underscore the potential of this combination therapy to improve outcomes for patients with the KRASG12C mutation.
Mechanism of Action
Krazati is a small-molecule inhibitor targeting the KRASG12C mutation. It is taken orally twice daily and works by specifically inhibiting the KRASG12C protein, thereby hindering cancer cell proliferation. Krazati is already approved in the U.S. for treating specific cases of non-small cell lung cancer (NSCLC).
Continued Development and Confirmatory Trials
As part of the FDA’s accelerated approval pathway, the continued authorization of Krazati for this indication may depend on the results from a confirmatory trial. BMS is committed to further evaluating Krazati through ongoing clinical development programs to ensure its long-term efficacy and safety.
Significance of the Approval
Wendy Short Bartie, Senior Vice President of U.S. Oncology and Hematology at BMS, emphasized the importance of this approval, describing it as “an important milestone” for both the company and CRC patients. She highlighted the significance of Krazati being the first KRASG12C inhibitor approved for CRC, extending beyond its use in NSCLC.
Strategic Acquisition and Expansion
BMS’s acquisition of Krazati came through its recent $5.8 billion buyout of Mirati Therapeutics, which was finalized in January. This acquisition not only brought Krazati into BMS’s portfolio but also included multiple other promising oncology assets, such as MRTX1719. BMS has expressed enthusiasm about the potential of these assets, particularly given the encouraging early efficacy data observed across several tumor types, including NSCLC and melanoma.
Future Directions
Giovanni Caforio, the then Chief Executive Officer at BMS, articulated the company’s excitement about incorporating these new assets into their oncology portfolio. He underscored BMS’s commitment to accelerating the development of these treatments to offer more options for cancer patients. This strategic acquisition and the subsequent FDA approval of Krazati mark a pivotal step in BMS’s mission to enhance targeted cancer therapies.
Conclusion
The FDA’s accelerated approval of Krazati for treating colorectal cancer patients with the KRASG12C mutation represents a significant advancement in oncology. With its proven efficacy in clinical trials and its strategic importance to BMS’s expanding oncology portfolio, Krazati offers new hope for patients battling this challenging form of cancer. As BMS continues to evaluate and develop Krazati, the future looks promising for further advancements in targeted cancer treatments.
Related: Bristol Myers Squibb & Future M&A’s